Industry News
Formosa Pharmaceuticals Partners with Cipla to Launch APP13007 in 11 Countries

Formosa Pharmaceuticals has signed an exclusive licensing agreement with Cipla for the commercializa...

read more
Formosa Pharmaceuticals Partners with Cipla to Launch APP13007 in 11 Countries
March 21, 2025
Bausch + Lomb Launches Arise: An Intelligent Cloud-Based Orthokeratology Lens Fitting System

Bausch + Lomb has announced the U.S. launch of Arise, an advanced lens fitting system that leverages...

read more
Bausch + Lomb Launches Arise: An Intelligent Cloud-Based Orthokeratology Lens Fitting System
March 20, 2025
OSRX Expands Medication Sizes and Introduces Direct-to-Patient Post-Op Kits

OSRX is expanding its pharmaceutical offerings with new medication sizes and direct-to-patient post-...

read more
OSRX Expands Medication Sizes and Introduces Direct-to-Patient Post-Op Kits
March 20, 2025
Nicox Completes Data Collection for NCX 470 Phase 3b Whistler Glaucoma Trial

Nicox has announced the completion of data collection for the Whistler Phase 3b clinical trial inves...

read more
Nicox Completes Data Collection for NCX 470 Phase 3b Whistler Glaucoma Trial
March 20, 2025
HanAll Biopharma Secures Orphan Drug Designation in Japan for Batoclimab to Treat Thyroid Eye Disease

HanAll Biopharma has received Orphan Drug Designation (ODD) from the Ministry of Health, Labor and W...

read more
HanAll Biopharma Secures Orphan Drug Designation in Japan for Batoclimab to Treat Thyroid Eye Disease
March 19, 2025
Iantrek’s Bio-Interventional Technology Shows Positive Glaucoma Surgery Results

Iantrek Corporation has released promising results from its two-year clinical study on bio-reinforce...

read more
Iantrek’s Bio-Interventional Technology Shows Positive Glaucoma Surgery Results
March 19, 2025
China Approves First IGF-1R Monoclonal Antibody for Thyroid Eye Disease, Innovent Biologics Announces

China has approved SYCUME, the country’s first monoclonal antibody treatment for thyroid eye disease...

read more
China Approves First IGF-1R Monoclonal Antibody for Thyroid Eye Disease, Innovent Biologics Announces
March 18, 2025
Stealth BioTherapeutics Reaches 50% Enrollment in Phase 3 ReNEW Study for Dry AMD

Stealth BioTherapeutics Inc. has achieved 50% of its enrollment target in the global Phase 3 ReNEW s...

read more
Stealth BioTherapeutics Reaches 50% Enrollment in Phase 3 ReNEW Study for Dry AMD
March 18, 2025
Harrow Launches VEVYE Access For All, Reducing Patient Barriers for Dry Eye Disease Treatment

Harrow, a North American eyecare pharmaceuticals company, has introduced VEVYE Access For All, a new...

read more
Harrow Launches VEVYE Access For All, Reducing Patient Barriers for Dry Eye Disease Treatment
March 18, 2025
More